1 min read
Palatin Targets First-Half 2027 Start for Lead Lipidated MC4R Peptide
Fiscal 2027 first-quarter priorities included IND-enabling activities for the peptide and development of oral small-molecule candidates.

Palatin Technologies, Inc. is targeting a Phase 1 study of its lead lipidated MC4R peptide in the first half of calendar 2027, while advancing work on oral candidates in its drug-development programs.
The company’s fiscal 2027 first-quarter priorities included IND-enabling activities for the peptide and development of oral small-molecule candidates.
Palatin is targeting the study for the first half of calendar 2027. The update describes work on the peptide as ongoing.